{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:21:55Z","timestamp":1794313315361,"version":"4.9.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Kidney transplant (KT) recipients experience high rates of cardiovascular disease, allograft dysfunction, and diabetes, negatively impacting long-term outcomes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and kidney benefits in non-KT recipients, but evidence in KT recipients remains limited. This systematic review and meta-analysis provide updated evidence on the efficacy and safety of SGLT2i and GLP-1RAs on KT recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>A comprehensive search of MEDLINE, Embase, and Cochrane databases was conducted through February 27, 2025. Data extraction, risk of bias assessment, and meta-analysis were performed using standardized methods with a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>A total of 32 studies, including 7834 KT recipients, were analyzed, comprising 21 studies (3856 patients) on SGLT2i and 12 studies (3978 patients) on GLP-1RAs. Their use was associated with reduced mortality and improved cardiovascular and kidney outcomes in matched control studies. Both agents promoted weight loss (SGLT2i: standardized mean difference \u20130.59; 95% confidence interval [CI], \u20131.04 to \u20130.15; GLP-1RA: standardized mean difference \u20130.27; 95% CI, \u20130.44 to \u20130.10) and hemoglobin A1c reduction (SGLT2i: mean difference, \u20130.33%; 95% CI, \u20130.55% to \u20130.12%; GLP-1RA: mean difference, \u20130.48%; 95% CI, \u20130.82% to \u20130.13%) while maintaining stable kidney function. SGLT2i increased serum magnesium levels and reduced uric acid levels. Safety analysis showed no increased risk of infections (SGLT2i) or pancreatitis (GLP-1RAs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>SGLT2i and GLP-1RA were associated with improved survival, cardiovascular, and kidney outcomes with a favorable safety profile. Future randomized controlled trials are necessary to confirm the efficacy and safety in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005496","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:00:28Z","timestamp":1753329628000},"page":"e217-e228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":35,"title":["SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","volume":"110","author":[{"given":"Sul A.","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruch\u00e1ma","family":"Verhoeff","sequence":"additional","affiliation":[{"name":"Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hullekes","sequence":"additional","affiliation":[{"name":"Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panupong","family":"Hansrivijit","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Brigham Women\u2019s Hospital, Boston, MA."},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham Women\u2019s Hospital, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron W.F.","family":"de Bruin","sequence":"additional","affiliation":[{"name":"Division of HPB and Transplant Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Porte","sequence":"additional","affiliation":[{"name":"Division of HPB and Transplant Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo V.","family":"Riella","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA."},{"name":"Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA."},{"name":"Department of Surgery and Department of Medicine, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"R1-20260119","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2215\/CJN.05021107","article-title":"Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation\/Kidney Disease Outcomes Quality Initiative (NKF\/KDOQITM) conference.","volume":"3","author":"Abecassis","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-20260119","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation.","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int"},{"key":"R3-20260119","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis.","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"R4-20260119","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"R5-20260119","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20260119","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R7-20260119","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20260119","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"R9-20260119","first-page":"CD009966","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20260119","doi-asserted-by":"crossref","first-page":"sfae018","DOI":"10.1093\/ckj\/sfae018","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis.","volume":"17","author":"Krisanapan","year":"2024","journal-title":"Clin Kidney J"},{"key":"R11-20260119","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.3390\/jcm13206181","article-title":"Safety and efficacy of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney transplant recipients: synthesis of evidence.","volume":"13","author":"Bellos","year":"2024","journal-title":"J Clin Med"},{"key":"R12-20260119","doi-asserted-by":"crossref","first-page":"100729","DOI":"10.1016\/j.trre.2022.100729","article-title":"Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: a systematic review.","volume":"37","author":"Lin","year":"2023","journal-title":"Transplant Rev (Orlando)"},{"key":"R13-20260119","doi-asserted-by":"crossref","first-page":"108604","DOI":"10.1016\/j.diabres.2020.108604","article-title":"Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: a systematic review and meta-analysis.","volume":"172","author":"Oikonomaki","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"R14-20260119","doi-asserted-by":"crossref","first-page":"101627","DOI":"10.1016\/j.diabet.2025.101627","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus.","volume":"51","author":"Diker Cohen","year":"2025","journal-title":"Diabetes Metab"},{"key":"R15-20260119","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.diabet.2025.101624","article-title":"Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus.","volume":"51","author":"Diker Cohen","year":"2025","journal-title":"Diabetes Metab"},{"key":"R16-20260119","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study.","volume":"9","author":"Lim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R17-20260119","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The Efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients.","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"R18-20260119","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients.","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat Commun"},{"key":"R19-20260119","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12933-025-02649-0","article-title":"Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients.","volume":"24","author":"Lin","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20260119","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/TP.0000000000004945","article-title":"Glucagon-like peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes mellitus.","volume":"108","author":"Dotan","year":"2024","journal-title":"Transplantation"},{"key":"R21-20260119","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.transproceed.2021.08.042","article-title":"Institutional experience with new antidiabetic drugs in kidney transplant.","volume":"53","author":"Yugueros Gonz\u00e1lez","year":"2021","journal-title":"Transplant Proc"},{"key":"R22-20260119","doi-asserted-by":"crossref","first-page":"e15144","DOI":"10.1111\/ctr.15144","article-title":"Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.","volume":"37","author":"Mahmoud","year":"2023","journal-title":"Clin Transplant"},{"key":"R23-20260119","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.transproceed.2024.12.009","article-title":"Use of SGLT2i in non-diabetic kidney transplant recipients.","volume":"57","author":"Quilis","year":"2025","journal-title":"Transplant Proc"},{"key":"R24-20260119","doi-asserted-by":"crossref","first-page":"e15383","DOI":"10.1111\/dme.15383","article-title":"Efficacy and safety of sodium\u2013glucose co-transporter-2 inhibitors in kidney transplant recipients with diabetes mellitus.","volume":"41","author":"Buckley","year":"2024","journal-title":"Diabet Med"},{"key":"R25-20260119","doi-asserted-by":"crossref","first-page":"12879","DOI":"10.3389\/ti.2024.12879","article-title":"SGLT2 inhibitors correct fluid overload in adult kidney transplant recipients\u2014a prospective observational study.","volume":"37","author":"Schork","year":"2024","journal-title":"Transpl Int"},{"key":"R26-20260119","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s11255-023-03645-7","article-title":"The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers.","volume":"55","author":"Demir","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"R27-20260119","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1097\/TXD.0000000000001228","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients.","volume":"7","author":"Hisadome","year":"2021","journal-title":"Transplant Direct"},{"key":"R28-20260119","doi-asserted-by":"crossref","first-page":"e14718","DOI":"10.1111\/ctr.14718","article-title":"Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.","volume":"36","author":"Lemke","year":"2022","journal-title":"Clin Transplant"},{"key":"R29-20260119","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus.","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"R30-20260119","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study.","volume":"16","author":"S\u00e1nchez Fructuoso","year":"2023","journal-title":"Clin Kidney J"},{"key":"R31-20260119","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"key":"R32-20260119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients.","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"key":"R33-20260119","doi-asserted-by":"crossref","first-page":"e00185","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients.","volume":"4","author":"Song","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"R34-20260119","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.","volume":"29","author":"Str\u00f8m Halden","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R35-20260119","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/dom.15035","article-title":"Safety and efficacy of sodium-glucose co-transporter-2 inhibitors in patients with kidney transplantation and diabetes mellitus.","volume":"25","author":"Yeggalam","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R36-20260119","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"R37-20260119","doi-asserted-by":"crossref","first-page":"848","DOI":"10.34067\/KID.0000000706","article-title":"Safety and efficacy of liraglutide and semaglutide in kidney transplant recipients.","volume":"6","author":"Kahwaji","year":"2025","journal-title":"Kidney360"},{"key":"R38-20260119","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4093\/dmj.2020.0180","article-title":"Dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: a retrospective review.","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab J"},{"key":"R39-20260119","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/TXD.0000000000000971","article-title":"The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients.","volume":"6","author":"Kukla","year":"2020","journal-title":"Transplant Direct"},{"key":"R40-20260119","first-page":"100343","article-title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or post-transplant diabetes.","volume":"36","author":"Mahzari","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"R41-20260119","doi-asserted-by":"crossref","first-page":"e15057","DOI":"10.1111\/dme.15057","article-title":"Glucagon-like peptide-1 receptor analogues in renal transplant recipients with diabetes: medium term follow of patients from a single UK centre.","volume":"40","author":"Mallik","year":"2023","journal-title":"Diabet Med"},{"key":"R42-20260119","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.nefroe.2024.11.007","article-title":"Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients.","volume":"44","author":"Vigara","year":"2024","journal-title":"Nefrologia (Engl Ed)"},{"key":"R43-20260119","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1210\/clinem\/dgad177","article-title":"Possible advantage of glucagon-like peptide 1 receptor agonists for kidney transplant recipients with type 2 diabetes.","volume":"108","author":"Sato","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20260119","first-page":"759","article-title":"The sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease with or without kidney transplantation\u2014a single centre study.","volume":"125","author":"Kleinova","year":"2024","journal-title":"Bratisl Lek Listy"},{"key":"R45-20260119","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ekir.2024.11.033","article-title":"Sodium-glucose cotransporter-2 inhibitor in diabetic and nondiabetic renal transplant recipients.","volume":"10","author":"Maigret","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R46-20260119","doi-asserted-by":"crossref","first-page":"20543581241293202","DOI":"10.1177\/20543581241293202","article-title":"Single center experience with sodium-glucose co-transporter-2 inhibitors (SGLT2i) in kidney transplant recipients with diabetes.","volume":"11","author":"Angjeli","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"R47-20260119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/jcm14020651","article-title":"Utilization trends of glucose-lowering medications among adult kidney transplant recipients with type 2 diabetes in the United States.","volume":"14","author":"Hansrivijit","year":"2025","journal-title":"J Clin Med"},{"key":"R48-20260119","doi-asserted-by":"crossref","first-page":"e031805","DOI":"10.1161\/JAHA.123.031805","article-title":"Comparison of effectiveness among different sodium-glucose cotransoporter-2 inhibitors according to underlying conditions: a network meta-analysis of randomized controlled trials.","volume":"13","author":"Kani","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R49-20260119","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R50-20260119","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule.","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab"},{"key":"R51-20260119","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","article-title":"Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers.","volume":"9","author":"Lee","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R52-20260119","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"R53-20260119","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials.","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R54-20260119","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/tri.13932","article-title":"Post-kidney transplant serum magnesium exhibits a U-shaped association with subsequent mortality: an observational cohort study.","volume":"34","author":"Panthofer","year":"2021","journal-title":"Transpl Int"},{"key":"R55-20260119","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"R56-20260119","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials.","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:00:21Z","timestamp":1768834821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005496","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}